New manufacturing chief at Schering-Plough
Schering-Plough names a new head of manufacturing as part of a
drive to bring control of the production supply chain under a new
€500m charge as Degussa restructures
Degussa has been forced to take a €500 million charge in its fine
chemicals business unit as it copes with the current adverse
Cambrex re-jigs Rutherford deal
US life science chemicals company Cambrex has altered the terms of
its agreement to sell Rutherford Chemicals and will make a slightly
higher loss on the new transaction.
Akzo profits down, as expected
Dutch pharmaceuticals, chemicals and coatings group Akzo Nobel has
reported a 23 per cent decline in third-quarter earnings, roughly
in line with expectations, on the back of continued pressure on its
Hike in profits at H&R Wasag
Germany's H&R Wasag is forecasting higher-than-expected profits
in 2003, helped by a reduction in oil prices since the end of the
war in Iraq.
Cambrex extends Ontak contract
Cambrex Bio Science has won an additional five-year contract to
manufacture Ontak, a biopharmaceutical product developed by Ligand
Chugai to claim top spot for bio production
Chugai says it is building facilities that will give it the largest
bioreactor capacity for biologicals production - at 85,000L - of
any company in the world by 2007.
Ireland's DPS sets out on European charge
DPS Engineering, an Irish engineering firm which specialises in
providing services to the pharmaceutical sector says it is planning
to create 250 jobs over the next five years as it continues a major
growth phase in its business in...
Hermes hikes production capacity
Hermes Arzneimittel buys a second pharmaceutical manufacturing site
from Viatris in a move which triples the number of staff working on
MG exits chemicals business
MG Technologies has decided to sell off its chemicals businessesand
concentrate on process technology and components.
Rhodia CEO quits
Troubled chemicals group Rhodia sees its CEO depart as the company
announces another restructuring round that will see €600m in
divestments by end-2004.
DSM culls US pharma plant
DSM has said that it has decided to decommission manufacturing of
pharma chemicals at its location in Greenville, US. Production
operations will cease in the course of 2004.
Cardinal Health buys Gala
Cardinal Health is to acquire 100 per cent ownership of protein
production specialist Gala Biotech for $15.5 million (€13.2m)in a
move to bolster its drug development services business.
Silica venture in Japan
Degussa and Shionogi set up a new joint venture company in Japan to
sell precipitated silica, silica gel and matting agents, used as
Chemicals follow crops as Bayer reorganises
Germany's Bayer has continued the revamp of its business units by
setting up its chemicals, technology services and healthcare
activities as three separate legal entities. The move follows the
carve-out of Bayer CropScience a...